Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Zuclomiphene citrate
Veru-944 · 1 trial · 1 indication
Percentage of change in frequency of moderate to severe hot flashes at 6 weeks
| Arm | Type | Description |
|---|---|---|
| Veru-944 10 mg | EXPERIMENTAL | Veru-944 10 mg daily |
| Veru-944 50 mg | EXPERIMENTAL | Veru-944 50 mg daily |
| Placebo | PLACEBO_COMPARATOR | Placebo daily |
| Name | Type | Description |
|---|---|---|
| Veru-944 | DRUG | Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT |
| Placebo | DRUG | Placebo |
Inclusion Criteria 1. Be over 18 years of age; 2. Be able to communicate effectively with the study personnel; 3. Have histologically confirmed prostate cancer; 4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 3 months prior to randomization; 5. Be continued on an LHRH ...
Top 20 of 49 competitors
Veru-944 is being developed to treat hot flashes in men with advanced prostate cancer. It is an investigational small molecule studied in a Phase 2 trial of 93 male patients with metastatic prostate cancer. It is not approved for any indication and remains in clinical development.
Veru-944 targets the estrogen receptor. By acting on this receptor, the drug is designed to reduce hot flashes in men undergoing treatment for advanced prostate cancer. The estrogen receptor is the molecular target identified for this small molecule.
Veru-944 is being developed by Veru Inc., a biopharmaceutical company whose common stock trades on the Nasdaq under the ticker symbol VERU. Veru Inc. is the sponsor of the clinical program evaluating Veru-944 in metastatic prostate cancer.
Veru-944 is in Phase 2 development. The completed Phase 2 study evaluated the drug in men with advanced prostate cancer. Veru-944 is investigational and has not been approved by the FDA for any indication.
Veru-944 has been studied in one clinical trial, NCT03646162, titled Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer. This Phase 2 trial enrolled 93 participants in the United States and is now completed.
The Phase 2 trial NCT03646162 was a randomized, double-blind, placebo-controlled study of Veru-944 in men with metastatic prostate cancer. It enrolled 93 male participants aged 18 years and older across sites in the United States and has been completed.